Volume 7, Issue 3, Pages (March 2010)

Slides:



Advertisements
Similar presentations
Volume 35, Issue 4, Pages (August 2009)
Advertisements

Volume 15, Issue 6, Pages (June 2012)
Zilong Qiu, Anirvan Ghosh  Neuron 
Volume 49, Issue 6, Pages (March 2013)
Volume 55, Issue 1, Pages (July 2014)
Volume 19, Issue 4, Pages (August 2005)
by Wu-Guo Deng, Ying Zhu, and Kenneth K. Wu
Volume 23, Issue 6, Pages (December 2005)
Volume 38, Issue 5, Pages (June 2010)
Volume 30, Issue 3, Pages (March 2009)
Volume 36, Issue 2, Pages (October 2009)
Tat Competes with CIITA for the Binding to P-TEFb and Blocks the Expression of MHC Class II Genes in HIV Infection  Satoshi Kanazawa, Takashi Okamoto,
Cellular DDX21 RNA Helicase Inhibits Influenza A Virus Replication but Is Counteracted by the Viral NS1 Protein  Guifang Chen, Chien-Hung Liu, Ligang.
Volume 23, Issue 1, Pages (July 2006)
A Mechanism for Inhibiting the SUMO Pathway
Volume 39, Issue 1, Pages (July 2010)
Rui Pedro Galão, Suzanne Pickering, Rachel Curnock, Stuart J.D. Neil 
SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency
Eun-Joo Kim, Jeong-Hoon Kho, Moo-Rim Kang, Soo-Jong Um  Molecular Cell 
Yongli Bai, Chun Yang, Kathrin Hu, Chris Elly, Yun-Cai Liu 
Volume 10, Issue 1, Pages (July 2011)
Volume 21, Issue 2, Pages (February 2017)
Volume 38, Issue 1, Pages (April 2010)
Evidence that HIV-1 Encodes an siRNA and a Suppressor of RNA Silencing
Volume 38, Issue 5, Pages (June 2010)
Ras Induces Mediator Complex Exchange on C/EBPβ
SUMO Promotes HDAC-Mediated Transcriptional Repression
An Acetylation Switch in p53 Mediates Holo-TFIID Recruitment
Direct Interactions of OCA-B and TFII-I Regulate Immunoglobulin Heavy-Chain Gene Transcription by Facilitating Enhancer-Promoter Communication  Xiaodi.
Volume 29, Issue 2, Pages (February 2008)
Xiaolong Wei, Hai Xu, Donald Kufe  Cancer Cell 
Volume 93, Issue 5, Pages (May 1998)
Yuming Wang, Jennifer A. Fairley, Stefan G.E. Roberts  Current Biology 
Vanessa Brès, Tomonori Yoshida, Loni Pickle, Katherine A. Jones 
Volume 25, Issue 3, Pages (February 2007)
The TRIM Family Protein KAP1 Inhibits HIV-1 Integration
Volume 92, Issue 4, Pages (February 1998)
Histone Deimination Antagonizes Arginine Methylation
Volume 13, Issue 6, Pages (June 2013)
Volume 38, Issue 3, Pages (May 2010)
HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress  Nirmalya Sen, Rajni Kumari, Manika Indrajit.
Volume 17, Issue 1, Pages (January 2015)
c-Src Activates Endonuclease-Mediated mRNA Decay
Volume 15, Issue 4, Pages (August 2004)
Volume 9, Issue 3, Pages (March 2009)
Andrei Kuzmichev, Thomas Jenuwein, Paul Tempst, Danny Reinberg 
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Volume 19, Issue 6, Pages (September 2005)
Volume 48, Issue 1, Pages (October 2012)
Cellular 5′-3′ mRNA Exonuclease Xrn1 Controls Double-Stranded RNA Accumulation and Anti-Viral Responses  Hannah M. Burgess, Ian Mohr  Cell Host & Microbe 
Two Functional Modes of a Nuclear Receptor-Recruited Arginine Methyltransferase in Transcriptional Activation  María J. Barrero, Sohail Malik  Molecular.
Amanda O'Donnell, Shen-Hsi Yang, Andrew D. Sharrocks  Molecular Cell 
Volume 39, Issue 1, Pages (July 2010)
Volume 125, Issue 4, Pages (May 2006)
Rodney P. DeKoter, Hyun-Jun Lee, Harinder Singh  Immunity 
Fan Yang, Huafeng Zhang, Yide Mei, Mian Wu  Molecular Cell 
The PHD Finger/Bromodomain of NoRC Interacts with Acetylated Histone H4K16 and Is Sufficient for rDNA Silencing  Yonggang Zhou, Ingrid Grummt  Current.
Volume 29, Issue 1, Pages (January 2008)
Volume 16, Issue 16, Pages (August 2006)
Volume 14, Issue 2, Pages (April 2004)
Volume 49, Issue 2, Pages (January 2013)
Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB
Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB  Wei-Chien Huang, Tsai-Kai Ju, Mien-Chie.
Volume 55, Issue 1, Pages (July 2014)
Volume 10, Issue 1, Pages (July 2011)
Volume 23, Issue 2, Pages (August 2005)
Volume 14, Issue 1, Pages (July 2013)
Volume 129, Issue 5, Pages (June 2007)
Volume 41, Issue 4, Pages (February 2011)
Volume 6, Issue 3, Pages (March 1997)
Presentation transcript:

Volume 7, Issue 3, Pages 234-244 (March 2010) The Cellular Lysine Methyltransferase Set7/9-KMT7 Binds HIV-1 TAR RNA, Monomethylates the Viral Transactivator Tat, and Enhances HIV Transcription  Sara Pagans, Steven E. Kauder, Katrin Kaehlcke, Naoki Sakane, Sebastian Schroeder, Wilma Dormeyer, Raymond C. Trievel, Eric Verdin, Martina Schnolzer, Melanie Ott  Cell Host & Microbe  Volume 7, Issue 3, Pages 234-244 (March 2010) DOI: 10.1016/j.chom.2010.02.005 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 In Vitro Methylation of Tat by Set7/9-KMT7 (A) Synthetic Tat (72 aa), histones, or recombinant GST-IκBα proteins were incubated with 3H-radiolabeled S-adenosyl-L-methionine (SAM) and increasing amounts of recombinant Set7/9-KMT7 (0, 0.5, 1, or 2 μg). Tat and histone H3 methylation were visualized by autoradiography (top panels). (B) Radioactive in vitro methylation reactions with synthetic Tat or histones and recombinant G9a enzyme (0, 1, or 2 μg). (C) In vitro methylation assays performed with short Tat peptides, recombinant Set7/9-KMT7, and 3H-SAM. Peptides were separated on Tris-Tricine gels and visualized by autoradiography. (D) In vitro methylation assays of ARM peptides (aa 45–58), containing either two lysines (WT) or alanine substitutions at positions K50 and K51. (E) MALDI TOF mass spectrometry of nonradioactive methylation reactions performed with the WT, K50A, or K51A ARM peptides. Peptides were incubated with Set7/9-KMT7 and SAM, SAM alone, or only the reaction buffer. (See also Figure S1.) Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 2 Tat Is Monomethylated at K51 in Cells (A) Dot blot analysis of biotinylated ARM peptides, either unmodified, mono-, di-, or trimethylated at K51 with α-meARM antibodies or SA-HRP. (B) Western blot analysis of in vitro methylation reactions with biotinylated synthetic Tat (12.5, 25, 50, and 100 ng), recombinant Set7/9-KMT7, and nonradioactive SAM with α-meARM antibodies or SA-HRP. (C) Immunoprecipitations of WT or mutant K51A Tat/FLAG in 293 cells, followed by western blotting with α-meARM or α-FLAG antibodies. (D) Immunoprecipitation/western blot analysis of Tat/FLAG coexpressed with Set7/9-KMT7 in 293 cells. The α-meARM antibodies were preincubated with milk, a 10 × molar excess of K51-monomethylated ARM peptide, or a 10 × molar excess of nonmodified ARM peptide. (E) Immunoprecipitation of Tat/FLAG in Jurkat A2 cells treated with TNF-α followed by western blotting with α-meARM or α-FLAG antibodies. Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 3 Set7/9-KMT7 Activates Tat Transactivation through K51 Methylation (A) Cotransfections in HeLa cells of expression vectors for WT or catalytically inactive Set7/9-KMT7 (H297A; 150 ng), with the indicated amounts of Tat expression vector and the HIV LTR luciferase reporter (200 ng). In parallel, cotransfections were performed with the EF-1α-RL reporter (20 ng) and WT or catalytically inactive Set7/9-KMT7 (H297A; 150 ng). Luciferase or Renilla values were analyzed 24 hr after transfections. The average of three independent experiments (mean ±SEM) is shown; ∗ corresponds to a p value <0.05 and ∗∗ to a p value <0.01 compared to cells transfected with vector control. (B) siRNA-mediated knockdown of Set7/9-KMT7 in HeLa cells. Cells were cotransfected with the HIV LTR luciferase construct (200 ng) and increasing amounts of expression vectors for WT or mutant K51A Tat/FLAG (0, 10, 50, 250 ng) 48 hr after siRNA transfection. Measurements of luciferase activity and western blotting were performed 24 hr after plasmid transfections. Luciferase values represent the average (mean ±SEM) of three experiments; ∗ corresponds to a p value <0.05 and ∗∗ to a p value <0.01 compared to control cells expressing WT Tat. (C) Transcriptional activity of TatK51A and TatK51R mutants in Set7/9-KMT7 knockdown cells. Experiment was performed as in (B) with 250 ng of WT or mutant Tat/FLAG. Luciferase values represent the average (mean ±SEM) of three experiments. ∗ corresponds to a p value <0.05 compared to WT Tat-transfected cells. Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 4 Set7/9-KMT7 Regulates HIV Gene Expression in the Context of Lentiviral Infection (A) siRNA-mediated knockdown of Set7/9-KMT7 in latently infected Jurkat A2 cells. Three days after nucleofection of Set7/9-KMT7 or control siRNAs, western blotting was performed, and cells were stimulated with PMA for 12 hr or were left unstimulated. GFP expression was measured by flow cytometry. The average (mean ±SEM) of three independent experiments is shown, ∗ corresponds to a p value <0.05 compared to control siRNA-transfected cells. (B) shRNA-mediated knockdown of Set7/9-KMT7 in CD4+T cells. Primary CD4+ T cells isolated from uninfected blood donors were infected first with lentiviral particles encoding shRNAs against Set7/9-KMT7 and second with a GFP-tagged reporter virus in the background of HIVNL4-3 or a lentiviral vector expressing GFP from the EF-1α promoter. GFP expression within shRNA-expressing cells (as marked by mCherry expression) is expressed relative to cells expressing nontargeting shRNA control. Average (mean ±SD) from triplicate experiments performed with three different donors (HIV GFP) or a single donor (HIV [EF-1α] GFP) is shown. Western blotting was performed in Jurkat cells transduced with indicated shRNAs and sorted for mCherry expression. (See also Figure S2.) Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 5 In Vivo Recruitment of Set7/9-KMT7 to the HIV LTR (A) Chromatin immunoprecipitation analysis of Set7/9-KMT7 in Jurkat A2 cells treated with PMA for 4 hr or left unstimulated. Real-time PCR was used to quantify the enrichment of indicated DNA regions after immunoprecipitation with α-Set7/9-KMT7 antibodies. Quantities of immunoprecipitated DNA were normalized to input DNA and expressed relative to the β-actin control. Three independent experiments were performed with similar outcome. Average (mean ±SD) of three PCR reactions of one experiment is shown. (B) CoIP of Tat/FLAG and endogenous Set7/9-KMT7 in Jurkat A2 cells treated with TNF-α. Cellular lysates were immunoprecipitated with α-Set7/9-KMT7 antibodies followed by western blotting with α-Set7/9-KMT7 or α-FLAG antibodies. (C) CoIP of WT and K51A mutant Tat with endogenous Set7/9-KMT7 in 293 cells. Immunoprecipitations were performed with α-Set7/9-KMT7 antibodies or agarose beads alone and analyzed by western blotting with α-Set7/9-KMT7 or α-FLAG antibodies. (See also Figure S3.) Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 6 Set7/9-KMT7 Binds TAR RNA and Tat/P-TEFb (A) Gel shift assays of recombinant Set7/9-KMT7 (0, 50, 150, and 500 ng) and radiolabeled WT or bulge mutant (Δbulge) TAR RNA probes. A 10 × excess of nonradiolabeled TAR RNA was included to compete for binding with the radiolabeled probe. (See also Figure S4A.) (B) Supershift assays with α-Set7/9-KMT7 antibodies (7 μg) or control rabbit IgGs in reactions containing Set7/9-KMT7 (1 μg) and radiolabeled WT TAR RNA probe. (C) Gel shift assays with full-length or N-terminally truncated Set7/9-KMT7 (0, 0.1, 0.3, 1 μg) and radiolabeled WT TAR RNA probe. (D) Tat and P-TEFb binding to TAR in the presence of Set7/9-KMT7. Radiolabeled TAR RNA probes (WT or Δloop) were incubated with synthetic Tat protein (0, 2.5, 10, and 40 ng) in the absence or presence of recombinant Set7/9-KMT7 (500 ng). The same reactions were performed in the presence of recombinant Cyclin T1/CDK9 (400 ng). (E) CoIP of Cyclin T1 and Set7/9-KMT7 in the presence of Tat. 293 cells were cotransfected with HA-Cyclin T1 and Tat/FLAG expression vectors. Cell lysates were immunoprecipitated with α-Set7/9-KMT7 antibodies followed by western blotting with α-Set7/9-KMT7, α-FLAG, and α-Cyclin T1 antibodies. (See also Figure S4B.) Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 7 Model of Set7/9-KMT7 Recruitment to the HIV LTR (A) Set7/9-KMT7 binds TAR bulge and loop sequences in newly synthesized HIV transcripts. (B) When Tat is produced, Set7/9-KMT7 engages into complex formation with Tat and P-TEFb and methylates K51 in Tat. See text for details. Cell Host & Microbe 2010 7, 234-244DOI: (10.1016/j.chom.2010.02.005) Copyright © 2010 Elsevier Inc. Terms and Conditions